Related by context. All words. (Click for frequent words.) 64 CINQUIL 63 pharmacoeconomics 63 clinical 62 efficacy tolerability 62 pharmacogenetic testing 62 QbD 61 pharmacokinetic equivalence 61 antiplatelet therapies 61 Referenced EEG 61 postapproval 61 clevidipine 61 pharmaco 61 PGx 61 topical NSAIDs 60 Pharmacoeconomics 60 MGN# 60 HDL Selective Delipidation 60 metabonomics 60 EmbraceAC 60 antiangiogenic agents 60 pharmacodynamic parameters 59 RE LY trial 59 PREVU x LT 59 viral kinetics 59 rEEG 59 Numoda 59 guideline concordant 59 pharmacogenetic 59 novel oral anticoagulant 59 Cardiotoxicity 59 oncological outcomes 59 Perforomist ™ Inhalation Solution 59 pharmacokinetic PK study 58 EGFR mutation status 58 dual antiplatelet 58 indications contraindications 58 psychopharmacological 58 GI motility disorders 58 EP #R 58 non pharmacological interventions 58 Dendreon Provenge 58 QOPI 58 therapeutic radiopharmaceuticals 58 Bergenstal 58 VBID 58 interventional therapies 58 Electronic Brachytherapy 58 Inflammatory diseases 58 BEXXAR therapeutic regimen 58 pharmacotherapeutic 58 PDE# inhibitors 58 riociguat 58 Zevalin consolidation 58 potency selectivity 58 nonpharmacologic 58 HORIZONS AMI 58 bioequivalency 58 Archimedes Model 58 fusion enhancers 58 pain palliation 58 chemoprevention trials 58 PROSTVAC TM 58 Dalbavancin 58 torezolid phosphate 58 nutrigenomic 58 QTinno 58 ASCEND HF 58 postmarket surveillance 58 AZILECT ® 57 prognostic indicators 57 OnDose TM 57 Ketotransdel 57 HEOR 57 ONCONASE R 57 therapeutic equivalence 57 Zemplar Capsules 57 KRN# 57 orally inhaled migraine 57 rALLy trial 57 EGS# 57 adjuvant therapies 57 Meta analyzes 57 non selective NSAIDs 57 pharmacologic therapies 57 antithrombotics 57 BEXXAR Therapeutic Regimen 57 delafloxacin 57 oral anticoagulation 57 preclinical efficacy 57 Alequel 57 Dual Opioid TM 57 MediGene focuses 57 ADVEXIN therapy 57 COX 2s 57 thetreatment 57 NICE SUGAR 57 Bioequivalence 57 metaanalysis 57 Trofex 57 ganetespib 57 investigational therapies 57 IMA# 57 Comparative effectiveness 57 AlloMap testing 57 Evoltra ® 57 tecarfarin 57 pharmacological therapies 57 PREVU x 57 DPX Survivac 57 Vaxfectin TM 57 pharmacotherapies 57 biologic plausibility 57 blinded randomized controlled 57 anti dyslipidemic 57 clinical pharmacology studies 57 BrachySil TM 57 eprescribing 57 trastuzumab DM1 57 Celgene Revlimid 57 EECP ® therapy 57 ColorectAlert TM 56 efficacious therapies 56 Sebivo 56 Ketotransdel TM 56 prospective observational studies 56 medicine EBM 56 NATRECOR ® 56 methodological limitations 56 microRNA profiling 56 biopsychosocial model 56 pharmacogenetic tests 56 ADME properties 56 treating neuropathic pain 56 CaPre TM 56 Rheumatologists 56 Myerburg 56 bardoxolone methyl 56 NP2 Enkephalin 56 Egrifta 56 oral taxane 56 NCCN guidelines 56 ticagrelor Brilinta 56 DIFICID 56 Hyphanox 56 Zometa zoledronic acid 56 Anavex #-# 56 antithrombotic therapy 56 Pharmacogenomic 56 ganaxolone 56 Hedgehog inhibitor 56 CRLX# 56 biologic DMARDs 56 antibiotic regimens 56 OvaRex R 56 pharmacoeconomic analysis 56 Intervention Effectiveness 56 dosimetric 56 Ereska 56 tanespimycin 56 NovaBay Aganocide compounds 56 APTIVUS R 56 clinically relevant 56 radiographic outcomes 56 OncoVEX GM CSF 56 molecular biomarkers 56 TAXUS VI 56 LibiGel ® 56 pharmacologic treatments 56 dermatologic diseases 56 cardiac repolarization 56 JAK inhibitor 56 Onconase 56 predictive biomarkers 56 oral dnaJP1 56 HCV protease inhibitors 56 ERYtech 56 Neuradiab 56 Cloretazine R 56 teratogenicity 56 ProSavin 56 Elio Evangelista senior 56 methodologic 56 Renal Cell Carcinoma RCC 56 OnDose 56 efficacy 56 immunotherapeutic vaccine 56 prescribers pharmacists 56 PROLARIS 56 including eniluracil ADH 56 nonclinical studies 56 Captisol enabled 56 eTag assays 56 empirically validated 56 BRCA testing 56 ICD therapy 56 CRMD# 56 SYNTAX trial 56 Rigorous scientific 56 arzoxifene 56 vidofludimus 56 indibulin 56 Theranostics 56 oncologic 56 Referenced EEG ® 56 cerebral oximetry 56 agomelatine 56 Pyridorin 56 LEVADEX ™ 56 PITX2 methylation 56 trastuzumab Herceptin ® 56 NTx ® -# 56 CB1 antagonists 56 candidate TNFerade biologic 55 OraTest R 55 biostatistical analysis 55 frameless radiosurgery 55 eprotirome 55 PREVU * LT 55 Altrazeal R 55 Pertuzumab 55 Supernus Pharmaceuticals 55 pharmacogenomic testing 55 Glybera R 55 VTE prevention 55 Oncotype 55 Phase IIIB IV 55 IMPROVE HF 55 kidney urologic 55 acetonide FA 55 thorough QT 55 pharmacokinetic pharmacodynamic 55 Triapine R 55 pharmacogenomic 55 epigenetic therapies 55 contra indications 55 Fabry Disease 55 immunotherapeutic approaches 55 ongoing Phase IIIb 55 Valdoxan 55 genomic biomarker 55 Panzem R NCD 55 OHR/AVR# 55 biomarker discovery validation 55 pregabalin Lyrica 55 VADT 55 pharmacodynamic properties 55 functional neuroimaging 55 diagnostic prognostic 55 Corus CAD 55 galiximab 55 CAPHOSOL 55 therapeutic regimens 55 Demonstrates Sustained 55 anti angiogenic agents 55 bio equivalence 55 venous thromboembolic disease 55 IOP lowering 55 postmarketing adverse 55 cystinosis patients 55 anticancer therapy 55 CA9 SCAN 55 Diastolic Heart Failure 55 lung cancer chemoprevention 55 dirucotide MBP# 55 Zelnorm Zelmac 55 vitro molecular diagnostic 55 Tolvaptan 55 MyVax R 55 RE LY ® 55 guanfacine extended release 55 PLAC test 55 relapsed MM 55 KOLs 55 intensive lipid lowering 55 EMPOWER TM 55 Aggrastat ® tirofiban hydrochloride 55 Combo Stent 55 AVERROES 55 multimodal analgesia 55 genomic biomarkers 55 sorafenib Nexavar 55 Temsirolimus 55 SUTENT ® 55 SNT MC# 55 MoxDuo IR 55 randomized controlled trials RCTs 55 Interferon beta 55 XP #L 55 Rebif ® 55 PROactive study 55 Pharmacokinetic 55 Phase IIIb study 55 StemEx R 55 neratinib 55 CaPSURE 55 biostatistical 55 deforolimus 55 cardiac revascularization 55 ZOLINZA 55 BRAF inhibitors 55 Clinical 55 TOLAMBA 55 predictive toxicology 55 Outpatient Setting 55 pharmacodynamic PD 55 monoclonal antibody therapeutics 55 Nesiritide 55 REMINYL ® 55 treating uterine fibroids 55 cardio renal 55 Modrenal 55 pharmacologic stress 55 Zavesca r 55 mechanical thrombectomy 55 Arranon 55 TransVax ™ 55 Catena ® 55 oncologic outcomes 55 spontaneous regression 55 gp# vaccine 55 INCB# [001] 55 Vaxfectin R 55 Archexin 55 PROCHYMAL 55 Sipuleucel T 55 Myocet 55 Aviptadil 55 aerosolized surfactant 55 Altastaph 55 morbidity mortality 55 CYPHER R Sirolimus eluting 55 QVAR 55 tigecycline 55 antithrombotic 55 preclinical pharmacology 55 Xcytrin R 55 EXPAREL ™ 55 PREOS 55 OncoVEX 55 vosaroxin 55 Golimumab 55 antihormonal 55 PK PD modeling 55 ONTARGET 55 evaluating REVLIMID 55 Actimmune ® 55 pharmacogenetics 55 Liprotamase 55 haematological cancers 55 cannabinor 55 paclitaxel poliglumex 55 Teriparatide 55 Combivir Kivexa 55 Campath alemtuzumab 55 EC Cysteamine 55 Randomized trials 55 companion diagnostics 55 reboxetine 55 intranasal delivery 55 chemopreventive agents 55 Perforomist TM formoterol fumarate 54 Tumor Response 54 biologic 54 Coronary CTA 54 favorable pharmacokinetic profile 54 PNH patients 54 KIF6 carriers 54 pharmacokinetics pharmacodynamics 54 poststroke depression 54 antipsychotic prescribing 54 Trandolapril 54 Multivariate logistic regression 54 Sentinel Lymph Node Biopsy 54 THALOMID 54 Randomized clinical trials 54 empiric therapy 54 Spiriva Handihaler 54 ACUITY trial 54 NeuroSTAT ® 54 Bioaccelerate compounds under 54 biomarker validation 54 KRAS status 54 LEUKINE 54 Zoraxel 54 solid organ transplantation 54 convenient dosing regimen 54 YONDELIS R 54 developmental neurotoxicity 54 atherosclerosis regression 54 Effient prasugrel 54 Comparative Effectiveness 54 null responder 54 ophthalmology dermatology cardiovascular disease 54 Pharmacoeconomic 54 analgesic efficacy 54 EECP therapy 54 neuroprotective agent 54 BACcel ™ system 54 atacicept 54 Hedgehog Pathway Inhibitor 54 renal anemia 54 PDE inhibitors 54 prognostic variables 54 BARI 2D 54 antiplatelet medications 54 Sanofi Aventis Taxotere 54 Predictive modeling 54 biomarker identification 54 Warfarin Coumadin 54 QTinno TM 54 Azedra 54 antiepileptics 54 haematologic 54 gastroenterological 54 Cancidas 54 echocardiographic parameters 54 antiangiogenic therapy 54 KRAS mutation 54 thromboprophylaxis 54 Pharmacodynamic 54 Helicobacter pylori eradication 54 constipation OIC 54 prognostic biomarkers 54 Roche Xeloda 54 obatoclax 54 tolevamer 54 oral NSAIDs 54 antirheumatic 54 HIF PH inhibitors 54 multivessel coronary artery 54 TNF alpha inhibitor 54 Phase IIb clinical trials 54 biopsychosocial 54 noninfectious uveitis 54 Fibrin Pad 54 cobiprostone 54 cMET 54 antiplatelets 54 allogeneic HSCT 54 tranilast 54 Octreolin 54 gynaecologic 54 therapeutic armamentarium 54 Fondaparinux 54 Endoscopic Ablation System 54 immunomodulation 54 successfully commercialize Iluvien 54 nomograms 54 tezampanel NGX# 54 glatiramer 54 sipuleucel T 54 RESOLUTE clinical 54 SILENOR 54 RE LY 54 MRgFUS 54 IVDs 54 anticholinergic agents 54 CYT# potent vascular disrupting 54 SinuNase TM 54 genotype phenotype 54 Intervention Effectiveness CATIE 54 renoprotective 54 LUNESTA brand eszopiclone 54 anidulafungin 54 MERLIN TIMI 54 Alequel ™ 54 convenient dosing regimens 54 MTWA testing 54 cognitive behavioral therapies 54 phase IIIb 54 immunosuppressive therapies 54 Altrazeal TM Silver 54 Clinical Antipsychotic Trials 54 CTAP# Capsules 54 Doribax 54 Nasulin ™ 54 dexanabinol 54 Bucindolol 54 NCCN Drugs 54 Telavancin 54 ACCORD Lipid 54 Cloretazine 54 vismodegib 54 psychopharmacologic 54 Zenvia ™ 54 perfusion CT 54 postoperative ileus POI 54 STRIDE PD 54 coronary CTA 54 tolerability pharmacokinetics 54 CARE HF 54 metabolics 54 MAGE A3 ASCI 54 ALTROPANE 54 lumiliximab 54 Endo PAT 54 indicates cardio circulatory 54 Overactive Bladder 54 dermatological diseases 54 endothelin antagonist 54 Rezular 54 MAA submission 54 postoperative atrial fibrillation 54 Pfizer inhaled insulin 54 nonadherence 54 Non inferiority 54 vitro ADME 54 eCME 54 vertebral subluxation 54 cyclophilin inhibitors 54 Immunotherapeutic 54 hormone therapy HT 54 noscapine 54 angiographic outcomes 54 RISPERDAL ® 54 IMiDs ® compound 54 BACcel 54 MoxDuo 54 #F FDG PET 54 PHX# 54 Paliperidone ER 54 MYCAMINE 54 mechanistic insights 54 biomedically 54 antiarrhythmic drug 54 pivotal bioequivalence 54 antitumour 54 mTOR inhibition 54 prospective multicenter study 54 Effexor venlafaxine 54 DCCR 54 Aflibercept 54 coexisting illnesses 54 NCQA accreditation 54 olanzapine LAI 54 probiotic supplementation 54 Bioavailability 54 ruxolitinib 54 interferon gamma 1b 54 diagnosing ADHD 53 rhITF 53 Glatiramer Acetate 53 Synavive ™ 53 PSMA ADC 53 p# biomarker 53 Isolagen Therapy 53 prospective nonrandomized 53 molecularly targeted therapies 53 AstraZeneca Brilinta 53 oxypurinol 53 Multiple logistic regression 53 pharmacokinetic profiles 53 invasive candidiasis 53 Optimata 53 ophthalmology dermatology 53 REACH Registry 53 REVEAL Registry 53 Retisert 53 liposomal amphotericin B 53 biomarker assays 53 Onrigin 53 PGxPredict tests 53 EECP R 53 ixabepilone 53 dalbavancin 53 hemodiafiltration HDF 53 therapeutics diagnostics 53 anticlotting drugs 53 Prospective Randomized 53 adjunctively 53 anticancer treatments 53 Velcade bortezomib 53 Limbrel 53 radiolabeled TM# 53 infusional 53 Genentech Tarceva 53 BLA filing 53 multitargeted 53 tolerability profiles 53 systemic immunosuppressive drugs 53 Oral NKTR 53 Phase #b/#a 53 HORIZONS AMI trial 53 intracranial stenosis 53 Gleevec Glivec 53 Syndax Pharmaceuticals Inc. 53 teriflunomide 53 cardiometabolic 53 ToGA 53 FibroScan ® 53 Renal Cancer 53 lipid lowering medication 53 immune modulating 53 Inhalation Solution 53 KRAS mutation status 53 antidepressive 53 IRX 2 53 oral antiplatelet 53 Onbrez Breezhaler 53 Cognitive behavioral 53 uric acid lowering 53 convergent validity 53 Amgen Vectibix 53 eculizumab therapy 53 clinical trials 53 Rheos System 53 Restanza TM 53 preclinically 53 atrasentan 53 Noxafil 53 validating biomarkers 53 CAM modalities 53 Phase IIb III 53 Randomized controlled 53 Xinlay 53 Tß4 53 Spiriva HandiHaler 53 Alequel TM 53 Itopride 53 Degarelix 53 metabolomic profiling 53 pharmacogenomics 53 carotid artery stenting 53 Postmarketing 53 CNS Therapeutics 53 ePRO solutions 53 randomized multicenter trial 53 Removab 53 GERD migraine headaches 53 Generx TM 53 periodically reassessed 53 Edge STudy 53 Q#IR 53 cediranib 53 Combidex 53 antianginal 53 FDG PET 53 Informed consent 53 molecular determinants 53 Altrazeal ® 53 CompuFlo 53 biobehavioral 53 transrectal ultrasound guided 53 Novartis Zometa 53 methodologically rigorous 53 novel therapeutic antibodies 53 Novavax VLP vaccine 53 allergen immunotherapy 53 Phase #/#a 53 tumor histology 53 Fully Covered Stent 53 LHRH antagonists 53 immunology oncology 53 DYSPORT TM 53 oxymorphone ER 53 midstage clinical 53 custirsen 53 TNF alpha antagonist 53 STEDESA 53 hoFH 53 Prosaptide 53 Screening Trial DMIST 53 PrevOnco 53 radezolid 53 deferiprone 53 Celator 53 CobaCyte 53 Deforolimus 53 Virulizin ® 53 Fingertip Formulary 53 trastuzumab DM1 T DM1 53 ICH guidelines 53 CBLC# 53 Prodarsan R 53 digitizing pathology 53 phase IIa clinical 53 myopathy rhabdomyolysis 53 antitumor effect 53 antimicrobial stewardship 53 Generx ™ 53 noncancer 53 Hedgehog agonist 53 SPIRIVA HandiHaler 53 L BLP# 53 macrolide antibiotics 53 edifoligide E2F Decoy 53 CIPN 53 urology oncology 53 etiological 53 detecting diagnosing 53 Ziprasidone 53 Dyax phage display 53 Elocalcitol 53 Tectin TM 53 ToleroMune 53 herpetic keratitis 53 OMAPRO ™ 53 bicifadine 53 anti thrombotics 53 DNA methylation markers 53 erythropoietic 53 ADVEXIN clinical 53 diagnostic molecular imaging 53 ELACYT 53 Cerashield 53 PROMETA protocols 53 enzastaurin 53 gepirone ER 53 trodusquemine 53 palifosfamide 53 zileuton CR 53 LLLT 53 neuro musculoskeletal 53 preventing recurrences 53 postoperative ileus 53 sorafenib tablets 53 Meets Primary Endpoint 53 ovarian suppression 53 rheumatologic 53 CR# vcMMAE 53 Hexvix 53 Subgroup analyzes 53 Plenaxis TM 53 Plenaxis R 53 Amgen Prolia 53 Civacir 53 SIRT1 activation 53 smoldering multiple myeloma 53 Gilead Viread 53 trastuzumab Herceptin 53 ADCS CGIC 53 Adnectin 53 calcineurin inhibitors 53 neurology immunology 53 OncoVex 53 alicaforsen enema 53 Szeinbach 53 micafungin 53 ACCOMPLISH 53 CHARM Added 53 biomarker discovery 53 plasma pharmacokinetics 53 faropenem 53 Exforge HCT 53 aflibercept VEGF Trap 53 mRCC 53 doxorubicin HCl 53 APOE genotype 53 alvimopan 53 BioDisc 53 LUMINATE 53 osteoporotic compression fractures 53 Diabetic Foot Ulcer 53 insulin analogs 53 oral deforolimus 53 adjuvant systemic 53 Interventional radiology 53 Squalamine 53 biomarkers predictive 53 Solorel TM 53 prescriber surveys 53 immatics 53 pharmacological interventions 53 ERYtech Pharma 53 Dacogen injection 53 stratifying patients 53 recombinant interferon 53 clinico pathological 53 Acute Ischemic Stroke 53 HEDIS R 53 HCV Protease Inhibitor 53 MEDCAC 53 Aryplase 53 preclinical pharmacokinetic 53 Vascugel ® 53 PRT# 53 Warner Chilcott Actonel 53 antibiotic prophylaxis 53 antiangiogenic agent 53 BRAF inhibitor 53 VerifyNow System 53 HuMax EGFr 53 chronic myocardial ischemia 53 Kogenate ® 53 pharmacodynamics PD 53 Ralivia TM 52 ClearPath HDR 52 fosbretabulin 52 personalized immunotherapy 52 MedPredict 52 pharmacokinetic interactions 52 Simulect 52 therapeutical 52 Entereg TM 52 QualityMetric 52 NuroPro R 52 postmarketing surveillance 52 CYP#D# inhibitor 52 velafermin 52 Pimavanserin 52 urology nephrology 52 ExTRACT TIMI 52 DXL# 52 Thalomid ® 52 systemic RNAi 52 TPI ASM8 52 empiric 52 Alexza Staccato 52 Rigel R# 52 inhaled iloprost 52 hematologic oncology 52 Bisphosphonate 52 atherothrombotic disease 52 Heart Transplant Recipients 52 lapatinib Tykerb 52 theranostic 52 randomized controlled clinical trials 52 stem cell transplantations 52 Luveris 52 Prednisporin TM 52 antimicrobial prophylaxis 52 Natalizumab 52 alvespimycin 52 Nanobodies ® 52 HERmark assay 52 Capesaris 52 novel therapeutic modality 52 ICAEL 52 colonoscopic 52 Desvenlafaxine 52 therapeutic monoclonal antibody 52 thoracoscopic lobectomy 52 TOCOSOL Camptothecin 52 DHEA supplementation 52 prasugrel Effient 52 AstraZeneca Iressa 52 G. biloba 52 bosutinib 52 rALLy 52 approvability 52 ChronVac C R 52 MabThera rituximab 52 paliperidone ER 52 Genedata Expressionist ® 52 Postmarket 52 Carfilzomib 52 patient centeredness 52 peginesatide 52 SPRIX ® 52 demonstrated antitumor activity 52 Pixuvri 52 pharmacodynamic effects 52 ARCOXIA 52 oral ridaforolimus 52 PORxin TM platforms 52 bovine thrombin 52 Zemiva TM 52 meta regression 52 spinal metastases 52 Symadex 52 thrombolytic agents 52 Inegy 52 Exelixis compounds 52 thiopurine 52 equine osteoarthritis 52 Proellex TM 52 AERx iDMS 52 skin sterol 52 Avastin Erbitux 52 INS# [001] 52 MMRC clinical trials 52 haemodynamic 52 Rasagiline 52 Sanvar R 52 gefitinib Iressa 52 CellerateRx 52 Aplenzin 52 Targretin 52 virology immunology 52 lipid lowering therapies 52 toxicogenomics 52 AAG geldanamycin analog 52 renin inhibition 52 aripiprazole Abilify 52 multicenter multinational 52 Aethlon Hemopurifier R 52 Stimuvax R 52 Xanafide 52 generic Copaxone 52 M# rationally 52 TQT studies 52 Zenvia Phase III 52 TKM ApoB 52 glatiramer acetate 52 p# inhibitor 52 gemifloxacin 52 ORENCIA R 52 warfarin dosing 52 hoFH patients 52 antithrombotic therapies 52 vernakalant hydrochloride 52 tasimelteon 52 GP IIb IIIa inhibitors 52 Firazyr ® 52 Pivotal Phase III 52 dentin hypersensitivity 52 evaluating tivozanib 52 erythropoietins 52 pharmacodynamic markers 52 persistency mortality 52 DVT PE 52 multicenter clinical trials 52 FDG-PET/CT 52 multimodality imaging 52 retrospective observational 52 PTK# 52 EXALGO 52 Xelox 52 Zenapax 52 Anidulafungin 52 Patient Outcomes 52 small molecule activators 52 pharmacologic intervention 52 budesonide MMX Phase III 52 CINTREDEKIN BESUDOTOX 52 Phase IIA 52 afamelanotide 52 alemtuzumab MS 52 oral mTOR inhibitor 52 RIGScan CR 52 HIFU therapy 52 Angiocept 52 relapsed SCLC 52 TYZEKA 52 PIX# [002] 52 my3KG 52 direct renin inhibition 52 biologic therapeutics 52 adipiplon 52 ibudilast 52 FFR measurements 52 humanised monoclonal antibody 52 HQK 52 linear pharmacokinetics 52 monoclonal antibody therapies 52 Sanofi Lovenox 52 human microdosing 52 nephrology oncology 52 PANVAC VF 52 Afatinib 52 immunosuppressive regimens 52 MoxDuo TM IR 52 Psoraxine R 52 Factor VIIa 52 acetabular fractures 52 immuno inflammatory 52 anti arrhythmic 52 Symbicort SMART 52 RhuDex ® 52 Chemophase 52 multicenter trials 52 NAVISTAR R 52 Dr. Sosne 52 Milnacipran 52 Cellegesic 52 PEGylated interferon beta 1a 52 cognitive enhancer 52 Dr. Kandzari 52 BR.# 52 galantamine 52 Adentri 52 DRX# ™ 52 AeroLEF TM 52 metaglidasen 52 Hyperbaric Oxygen Therapy HBOT 52 liprotamase 52 Max Neeman 52 AA Amyloidosis 52 thalidomide Thalomid 52 prospective multicentre 52 tipranavir 52 novel emulsion formulation 52 Tolevamer 52 bronchodilatory 52 OvaRex ® MAb 52 Aurora kinase inhibitors 52 combinability 52 Icatibant 52 teduglutide 52 miRview meso 52 eTag assay 52 NEUMUNE 52 Romidepsin 52 thromboembolic disease 52 Cx# [002] 52 ALK inhibitors 52 CNS hematology oncology 52 catheter occlusion 52 neurotrophic